相关实验视频

Updated: Jun 3, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

探索2型糖尿病患者的新兴药物治疗方法,这些患者患有高甘油三血症

Brian Tomlinson¹, Paul Chan²

¹Faculty of Medicine, Macau University of Science & Technology, Macau, China.

Expert opinion on pharmacotherapy

|January 10, 2025

概括

针对阿波利波蛋白C3 (apoC3) 和血管类3 (ANGPTL3) 的新型疗法显示出降低2型糖尿病 (T2D) 患者的甘油三的潜力,解决剩余心血管风险.

科学领域:

内分泌学在内分泌学.
心血管医学心血管医学
药理学药理学是一个学科.

背景情况:

以高甘油三,低HDL和小密度LDL为特征的动脉性脂质失调症,在2型糖尿病 (T2D) 中增加心血管 (CV) 风险.
这种失脂症代表了显著的残留心血管风险,即使LDL胆固醇在目标水平.

研究的目的:

审查2型糖尿病患者降低甘油三的新兴疗法.
专注于新型药物,包括pemafibrate,apoC3抑制剂和ANGPTL3抑制剂.

主要方法:

在PubMed数据库的文献搜索.
对纤维酸,apoC3抑制剂 (olezarsen,plozasiran) 和ANGPTL3抑制剂 (evinacumab) 的研究进行了综述.

主要成果:

纤维酸在T2D中降低了甘油三,但在PROMINENT研究中没有显示CV事件的减少.
ApoC3 抑制剂在降低甘油三水平方面表现出有效性,而像olezarsen 和 plozasiran 这样的药物正在研究联合高脂血症.
ANGPTL3 抑制剂,如 evinacumab,已被批准用于家族性高胆固醇血症,并可能为T2D 高甘油脂管理提供未来的好处.

结论:

目前用于T2D的甘油三降低疗法在有效性和CV益处证据方面存在局限性.
针对apoC3和ANGPTL3的新型疗法为治疗脱脂症和降低T2D残留心血管风险提供了有希望的途径.

关键词:

血管形成素类似的3 在C3的阿波利波蛋白中.这里是埃维纳库马布.这是Olezarsen的作品.纤维化纤维化这就是Plozasiran的原因.索尔宾西兰 (solbinsiran) 是一种这里是Zodasiran的星座.

更多相关视频

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

相关概念视频

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...